On the other hand, considering that after treatment prescription those patients with low Gal1 serum levels displayed high IL-6 serum levels, those with inadequate control of the disease with standard disease-modifying antirheumatic drugs might be considered candidates to intensify treatment through IL-6 signaling blockade, an effective tool in the treatment of RA patients [35]. This evidence concerns the gene LGALS1 and rheumatoid arthritis.